Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of…
BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of…